TVTX

THIOLA® EC (tiopronin)

Cystinuria

Quarterly Sales (Approved)

Exp Date

February 12, 2021 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: THIOLA® EC (tiopronin) for Cystinuria


WHAT IS THE CATALYST EVENT?

  • Report out on post-CRL FDA meeting


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS

PRESS RELEASE


Quarter's sales: $15M Q3/2020

2020 Revenue guidance: For the full year 2020, the Company anticipates net product sales will exceed the previous guidance of mid-single-digit percentage growth compared to 2019.



MECHANISM OF ACTION

  • The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.

Updated by HC

TVTX, Cystinuria, persistent kidney stones, defective transepithelial transport of cystine and dibasic amino acids in the kidney and intestine, THIOLA® EC (tiopronin) 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon